(Boursier.com) — TheraVet , a pioneering biotechnological company in the treatment of osteoarticular diseases in companion animals, today announces the signing of an exclusive distribution agreement with Nuzoa, a leading Spanish company in the distribution of veterinary products and services. This agreement represents an important step forward for the distribution of the BIOCERA-VET product range in Spain, one of the 5 largest European pet markets (along with France, the United Kingdom, Germany and Italy), with nearly 6, 7 million dogs and 3.7 million cats [1].
This alliance allows the Company to launch its products in Spain approximately 6 months ahead of schedule.

Under the terms of the agreement, Nuzoa will rely on its own commercial and marketing power in the veterinary field to promote and distribute BIOCERA-VET products in Spain. Nuzoa reached a turnover of approximately 135 million euros in 2021 and has 260 employees.

Enrico Bastianelli, President and CEO of TheraVet, comments: “We are very pleased to partner with Nuzoa for the distribution of our BIOCERA-VET range in Spain. This partnership will allow us to be closer to veterinarians thanks to Nuzoa’s striking force. , and satisfy the needs of the profession by offering our complete portfolio of BIOCERA-VET products”.

This distribution agreement includes products recently added to TheraVet’s bone substitute portfolio: BIOCERA-VET Bone Surgery RTU (2 references), BIOCERA-VET SmartGraft (4 references), BIOCERA-VET Granules (3 references) and BIOCERA-VET Osteosarcoma RTU (2 references). This range is perfectly positioned to meet the needs of veterinarians in terms of ease of use, compliance with current standards and results…

[1] FEDIAF Annual Report, 2020